These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27741010)

  • 101. Preoperative prediction of a pathologic complete response of esophageal squamous cell carcinoma to neoadjuvant chemoradiotherapy.
    Hamai Y; Hihara J; Emi M; Furukawa T; Murakami Y; Nishibuchi I; Nagata Y; Ibuki Y; Yamakita I; Kurokawa T; Okada M
    Surgery; 2018 Mar; ():. PubMed ID: 29519558
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol.
    Noordman BJ; Shapiro J; Spaander MC; Krishnadath KK; van Laarhoven HW; van Berge Henegouwen MI; Nieuwenhuijzen GA; van Hillegersberg R; Sosef MN; Steyerberg EW; Wijnhoven BP; van Lanschot JJ;
    JMIR Res Protoc; 2015 Jun; 4(2):e79. PubMed ID: 26121676
    [TBL] [Abstract][Full Text] [Related]  

  • 103. CT-based radiomic signatures for prediction of pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
    Yang Z; He B; Zhuang X; Gao X; Wang D; Li M; Lin Z; Luo R
    J Radiat Res; 2019 Jul; 60(4):538-545. PubMed ID: 31111948
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Endoscopic ultrasound measurements for detection of residual disease after neoadjuvant chemoradiotherapy for esophageal cancer.
    van der Bogt RD; Noordman BJ; Krishnadath KK; Roumans CAM; Schoon EJ; Oostenbrug LE; Siersema PD; Vleggaar FP; van Lanschot JJB; Spaander MCW
    Endoscopy; 2019 Apr; 51(4):326-332. PubMed ID: 30497088
    [TBL] [Abstract][Full Text] [Related]  

  • 105. High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer.
    Fang P; Jiang W; Davuluri R; Xu C; Krishnan S; Mohan R; Koong AC; Hsu CC; Lin SH
    Radiother Oncol; 2018 Sep; 128(3):584-590. PubMed ID: 29530432
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Computed tomography-based deep-learning prediction of neoadjuvant chemoradiotherapy treatment response in esophageal squamous cell carcinoma.
    Hu Y; Xie C; Yang H; Ho JWK; Wen J; Han L; Lam KO; Wong IYH; Law SYK; Chiu KWH; Vardhanabhuti V; Fu J
    Radiother Oncol; 2021 Jan; 154():6-13. PubMed ID: 32941954
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Intended use for a neoadjuvant chemoradiation response prediction test for locally advanced esophageal adenocarcinoma: a survey analysis of thoracic surgeons in the US.
    Shan W; Davies R; Choudhary J; Kotwal J; Kreisman A; Leonardi W; Shah P; Oelschlager K; Maetzold D
    Curr Med Res Opin; 2015 May; 31(5):1003-7. PubMed ID: 25734692
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Microscopic tumor spread beyond (echo)endoscopically determined tumor borders in esophageal cancer.
    Machiels M; van Montfoort ML; Thuijs NB; van Berge Henegouwen MI; Alderliesten T; Meijer SL; van Hooft JE; Hulshof MCCM
    Radiat Oncol; 2019 Dec; 14(1):219. PubMed ID: 31801574
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Relative metabolic tumor burden is associated with residual lymph node status after neoadjuvant chemoradiotherapy in locally advanced esophageal cancer.
    Lin D; Liu G; Yu Y; Shen Y; Wang H; Fang Y; Yin J; Shi H; Tan L
    Esophagus; 2021 Apr; 18(2):211-218. PubMed ID: 32737800
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Endoscopic evaluation of the esophageal cancer patient after chemoradiotherapy for persistent/recurrent cancer.
    Cosgrove ND; Mullady DK
    Dis Esophagus; 2018 Jul; 31(7):. PubMed ID: 29931309
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Predictive Value of Endoscopic Observations and Biopsy After Neoadjuvant Chemoradiotherapy in Assessing the Pathologic Complete Response of Patients With Esophageal Squamous Cell Carcinoma.
    Taghizadeh Kermani A; Ghanbarzadeh R; Joudi Mashhad M; Javadinia SA; Emadi Torghabeh A
    Front Oncol; 2022; 12():859079. PubMed ID: 35646696
    [TBL] [Abstract][Full Text] [Related]  

  • 112. NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial).
    van Heijl M; Omloo JM; van Berge Henegouwen MI; Busch OR; Tilanus HW; Bossuyt PM; Hoekstra OS; Stoker J; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Bilgen EJ; Ten Kate FJ; Boellaard R; Pruim J; Sloof GW; van Lanschot JJ
    BMC Med Phys; 2008 Jul; 8():3. PubMed ID: 18671847
    [TBL] [Abstract][Full Text] [Related]  

  • 113. PET could predict response to neoadjuvant therapy and long-term survival of patients with esophageal cancer.
    Wang WP; Wang KN; Chen LQ
    World J Surg; 2013 Apr; 37(4):930-1. PubMed ID: 23064737
    [No Abstract]   [Full Text] [Related]  

  • 114. Development and validation of a molecular tool to predict pathologic complete response in esophageal adenocarcinoma.
    Qian DC; Lefferts JA; Zaki BI; Brickley EB; Jackson CR; Andrici J; Sriharan A; Lisovsky M
    Dis Esophagus; 2022 Dec; 35(12):. PubMed ID: 35758407
    [TBL] [Abstract][Full Text] [Related]  

  • 115. [A Case of Remarkably Effective Chemoradiotherapy for Esophageal Cancer with Multiple Bone Metastasis].
    Tabuchi S; Nakagawa M; Koganezawa I; Yokozuka K; Hikita K; Kobayashi T; Sano T; Tomita K; Tsutsui R; Kuwabara H; Shigoka M; Chiba N; Hisada M; Katayanagi S; Kawachi S
    Gan To Kagaku Ryoho; 2019 Dec; 46(13):2419-2421. PubMed ID: 32156951
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Immune surveillance activation after neoadjuvant therapy for esophageal adenocarcinoma and complete response.
    Kotsafti A; Scarpa M; Cavallin F; Fassan M; Salmaso R; Porzionato A; Saadeh L; Cagol M; Alfieri R; Castoro C; Rugge M; Castagliuolo I; Scarpa M
    Oncoimmunology; 2020 Aug; 9(1):1804169. PubMed ID: 32923165
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Bite-on-bite biopsies for the detection of residual esophageal cancer after neoadjuvant chemoradiotherapy.
    van der Bogt RD; van der Wilk BJ; Oudijk L; Schoon EJ; van Lijnschoten G; Corporaal S; Nieken J; Siersema PD; Bisseling TM; van der Post RS; Quispel R; van Tilburg A; Oostenbrug LE; Riedl RG; Hol L; Kliffen M; Nikkessen S; Eyck BM; van Lanschot JJB; Doukas M; Spaander MCW
    Endoscopy; 2022 Dec; 54(12):1131-1138. PubMed ID: 35668664
    [TBL] [Abstract][Full Text] [Related]  

  • 118. MLDRL: Multi-loss disentangled representation learning for predicting esophageal cancer response to neoadjuvant chemoradiotherapy using longitudinal CT images.
    Yue H; Liu J; Li J; Kuang H; Lang J; Cheng J; Peng L; Han Y; Bai H; Wang Y; Wang Q; Wang J
    Med Image Anal; 2022 Jul; 79():102423. PubMed ID: 35429696
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Clinical Utility of Circulating Tumor Cells for Predicting Major Histopathological Response after Neoadjuvant Chemoradiotherapy in Patients with Esophageal Cancer.
    Gao X; Leow OQ; Chiu CH; Hou MM; Hsieh JC; Chao YK
    J Pers Med; 2022 Aug; 12(9):. PubMed ID: 36143225
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Salvage endoscopic resection in patients with esophageal adenocarcinoma after chemoradiotherapy.
    Noordzij IC; Curvers WL; Huysentruyt CJ; Nieuwenhuijzen GAP; Creemers GJ; van der Sangen MJC; Schoon EJ
    Endosc Int Open; 2018 Sep; 6(9):E1126-E1129. PubMed ID: 30211302
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.